Q2 2021 Eli Lilly and Co Earnings Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to Lilly's Q2 Earnings Call. (Operator Instructions) As a reminder, today's conference is being recorded. I would now like to turn the conference over to your host, Vice President of Investor Relations, Kevin Hern. Please go ahead.
Good morning. Thank you for joining us for Eli Lilly and Company's Q2 2021 Earnings Call. I'm Kevin Hern, Vice President of Investor Relations. And joining me on today's call are: Dave Ricks, Lilly's Chairman and CEO; Anat Ashkenazi, Chief Financial Officer; Dr. Dan Skovronsky, Chief Scientific and Medical Officer; Anne White, President of Lilly Oncology; Ilya Yuffa, President of Lilly Biomedicines; Mike Mason, President of Lilly Diabetes; and Jake Van Naarden, CEO of Loxo Oncology at Lilly. We're also joined by Lauren Zierke, Kento Ueha and Sara Smith of the Investor Relations team.
During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |